Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy

NCT00990587 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancy
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Myelodysplasia
Acute Myeloid Leukemia
Chronic Myelogenous Leukemia
Hodgkin's Disease

Interventions

DRUG: Ciclopirox Olamine

Sponsor

University Health Network, Toronto

Collaborators

[object Object]